Tower Research Capital LLC recently announced the acquisition of new stake in Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA). The institutional investor has increased its shareholding in the Healthcare company by 11.16% to 9533.0 shares with purchase of 957.0 shares. This fresh investment now brings its stake to 0.18% valued currently at $1554.0. In addition, Wells Fargo Bank, NA raised its holdings by 5.0 to 38.0 shares.
With over 29.52 million Sonoma Pharmaceuticals Inc. (SNOA) shares trading Tuesday and a closing price of $0.22 on the day, the dollar volume was approximately $6.5 million. The shares have shown a negative half year performance of -76.71% and its price on 12/05/23 gained nearly 15.86%. Currently, there are 13.68M common shares owned by the public and among those 13.08M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for SNOA have a consensus price objective of $3.25. The analysts have set the share’s price value over the next 12 months at a high of $3.25 and a low of $3.25. The average price target is 93.23% above its recent price level and an upside to the estimated low will see the stock gain 93.23% over that period. But an upside of 93.23% will see the stock hit the forecast high price target while median target price for the stock is $3.25.
Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 200,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Sonoma Pharmaceuticals Inc. are Fidelity Extended Market Index Fu, Fidelity Nasdaq Composite Index F, and Vanguard Extended Market Index Fu. Fidelity Extended Market Index Fu owns 29083.0 shares of the company’s stock, all valued at over $4741.0. Vanguard Extended Market Index Fu now owns shares totaling to 0.07% of the shares outstanding.
Shares of Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) opened at $0.201, up $0.01 from a prior closing price of $0.19. However, the script later moved the day high at 0.2600, up 15.86%. The company’s stock has a 5-day price change of 38.29% and -77.04% over the past three months. SNOA shares are trading -79.91% year to date (YTD), with the 12-month market performance down to -87.29% lower. It has a 12-month low price of $0.12 and touched a high of $2.68 over the same period. SNOA has an average intraday trading volume of 269.22K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 33.79%, -45.94%, and -74.43% respectively.
Institutional ownership of Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) shares accounts for 0.92% of the company’s 13.68M shares outstanding. Mutual fund holders own 1.65%, while other institutional holders and individual stakeholders account for 8.59% and 0.78% respectively.
It has a market capitalization of $3.08M and a beta (3y monthly) value of 1.33. The earnings-per-share (ttm) stands at -$1.48. Price movements for the stock have been influenced by the stock’s volatility, which stands at 18.09% over the week and 17.12% over the month.
Analysts forecast that Sonoma Pharmaceuticals Inc. (SNOA) will achieve an EPS of -$0.21 for the current quarter, -$0.17 for the next quarter and -$0.45 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.21 while analysts give the company a high EPS estimate of -$0.21. Earnings per share for the fiscal year are expected to increase by 18.51%, and 49.00% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Sonoma Pharmaceuticals Inc. (SNOA) as a “Strong Buy” at a consensus score of 1.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
